Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients

Inclusion Criteria: * males or non-pregnant females at least 20 year of age. * Diagnosis of, non-inflammatory breast adenocarcinoma and be referred for post-operative radiotherapy without concurrent chemotherapy. * Breast adenocarcinoma previously treated by lumpectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment. * With in situ breast cancer are also eligible * Prescribed concurrent hormone treatment with radiation treatment * Participants must be scheduled to receive 5 sessions of radiotherapy per week (1 session per day) for at least 5 weeks using standard (1.8 Gy to 2.0 Gy per session) for total dose of at least 45 Gy. * A time period of 3 weeks must elapse after chemotherapy and surgery before beginning this study. * Must be able to swallow medication. * Participant must give informed consent. Exclusion Criteria: * Bilateral breast cancer * Previous radiotherapy to the breast or chest. * Chemotherapy cocurrent with radiation treatment. * Receiving treatment with anti-coagulants, or anti-human epidermal growth factor receptor drugs, e.g., Iressa (gefitinib), Erbitux (cetuximab, C225), concurrently with their radiotherapy. * Prior breast reconstructions, implants, and/or expanders. * Known radiosensitivity syndromes, e.g., Ataxia-telangiectasia. * Collagen vascular disease, vasculitis, unhealed surgical sites, breast infections, or systemic lupus erythematosus. * Baseline blood tests that meet the following criteria: * Grade 2 change in …